ArticleBMC complementary medicine and therapies2026
Exploring the molecular mechanism of Er Miao San for treating rheumatoid arthritis based on network pharmacology.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to elucidate the molecular mechanism of Er Miao San (EMS) in treating rheumatoid arthritis (RA) by integrating network pharmacology, molecular docking, and experimental validation.
methodsUsing public databases, potential targets of EMS, RA-related targets, and NF-κB pathway targets were cross-referenced to identify common genes. These were analyzed via protein-protein interaction (PPI)network, GO/KEGG enrichment analyses (via DAVID), and hub gene identification (using Cytoscape and cytoHubba). Core predictions were validated by molecular docking, with therapeutic efficacy confirmed in adjuvant-induced arthritis (AA)rats and NF-κB pathway inhibition confirmed in TNF-α-induced fibroblast-like synoviocytes (FLSs).
resultsIntegrated analysis identified 34 common targets of Er Miao San (EMS) for rheumatoid arthritis (RA) treatment, with NFKBIA, RELA, and TNF recognized as the top hub genes. Molecular docking revealed stable binding between these targets and the core active components (fumarine, berberine, and wogonin). Experimentally, EMS alleviated joint pathology in AA rats and concentration-dependently suppressed TNF-α-induced proliferation of FLSs and the secretion of IL-1β and IL-6. Mechanistically, EMS inhibited NF-κB signaling by reducing the phosphorylation of IκBα and p65 and blocking the nuclear translocation of p65.
conclusionThe therapeutic effects of EMS on RA are mediated through the inhibition of the NF-κB signaling pathway, thereby elucidating its mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.